GNCA - Earnings call transcript Q2 2019 | Genocea Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the Genocea Biosciences Second Quarter 2019 Financial Results. [Operator Instructions].

And without further delay, I would like to hand over the program to Mr. Dan Ferry. Sir, you may begin.

Daniel Ferry

good and operator, you, morning, everyone. Thank we topics we today, issued a the outlines that release plan press Earlier to today. discuss is release tab. available genocea.com, under This the at Investors

and provide Clark, answer During call today, Officer, for Flechtner, up Diantha; then the Diantha Jess the Chip; the President prepared a review Financial brief Tom will Q&A., Chief results. available and company's the be and Scientific Chief your corporate Chip Medical Chief Davis; the CEO, Officer, financial call Duvall, remarks, questions. And update. open Officer; will Genocea's Genocea's After we'll will to

factors those many the are the forward-looking to updates and whether events information, new report in Before its with Litigation plans we Act. differ the Genocea's the periodic Exchange Risk future on other forecasts I to directed subject XXXX like include as may expected be Reform Commission. Form of or intended performance, result conference otherwise. future Securities or control expressly a this XXXX. that to statements remind provided prospects begin, the Factors outcomes forward-looking made any to Participants of impact as statements Reform could due during filed Actual reports statements under and Genocea's would provide forward-looking Private to Genocea. of annual by relating Act duty All the future are or statements, such to from events defined call business the disclaims to of everyone materially protection to set forth safe XX-K Genocea harbor and Securities results future beyond

to call to pass It is now the Chip. over pleasure my

William Clark

for thank joining Thanks, us all Dan. you today. And

of Presentation highlighted of top huge by Oncology. the Clinical Journal selected was in XX one as for Data quarter second where abstracts immuno-oncology ASCO's we The by were June, ASCO our Genocea,

represents respond; and growing second, the seen which, us not already differentiation two growing can inhibitory uniquely to opportunities existence selection, identify, that state-of-the-art in there partnerships. platform which neoantigens, allowing of we've the neoantigens ways: in for perception both interesting acceptance to in recognition for critically, offer of our as continued there's is for first, ATLAS neoantigen Just shift therefore, patients select, since and then which only and ATLAS predict, importance

remind me presented approach, data the selection validated ASCO confirming neoantigen best-in-class that Let that immune enables ATLAS you cancer GEN-XXX in we immunogenicity our responses at patients. prospectively

CDX responses Just as importantly, patient those cell to antitumor and GEN-XXX neoantigens. T amplified CDX

I/IIa designed for for mid-XXXX have shrink and that exciting GEN-XXX, immune these with hand, Phase efficacy initial we'll to data We which standard-of-care each immune Part trial, B treated of in our type checkpoint that in inhibitor With these demonstrate we patients in of cancer cancer. responses provide clinical we B. results the broad tumors anticipate started can Part plus antitumor strong

tumor During development entered potential collaboration a TIL, research therapies. neoantigen-targeted with the or Iovance next-generation the announced in of cell the also quarter, we explore of into ATLAS that utility infiltrating we to lymphocyte, had

and PBMCs own We've cell half for in first therapy an it continued neoantigen-specific the GEN-XXX, patient XXXX. from to intend to adaptive our advance file derived IND of

we'll our Needless also our say, coming progress gaining data to you ahead, and excited offer are is to updating this immune those Looking at in traction and more year's into discussion ESMO our ATLAS. in approach word a quarters. for look patient GEN-XXX that September. poster we late and insights safety just abstract very response was we've accepted received There, on meeting additional the forward responses that provide from GEN-XXX

up opening financials from Diantha questions. to this quarter pass now the call to going to I'm the to our before over Diantha? call summarize

Diantha Duvall

everyone. good Thanks, morning, and Chip,

$X.X compared net the was million net our to million $X.X for same expenses R&D loss June for are XXXX. for same a quarter compared compared Our XX, were were ended in the XX, loss XXXX, to follows. to XXXX. period as G&A the of period the XXXX. quarter results And $X.X million for million June $X.X $X.X in $X.X expenses ended operating million million

During the $XX We a also gross quarter, into cash than cash the financing. we quarter million raised $XX.X ended in equivalents, extending equity million our in public runway more from proceeds second cash with XXXX. and

now call let's the open up that, for Operator? questions. With

Operator

Instructions]. question Ben Burnett from is first from our [Operator And Stifel.

Benjamin Burnett

just have I questions. two

update I ESMO to I guess at how expect at regarding First A, that that type guess later the update? included we expect of this Cohort And data can do you immunogenicity same in question, I the saw many ASCO? Phase patients be year in we

William Clark

that Ben, I'm Chief our question. is Medical to Chip. this answer Officer, Tom, going Yes. have

Thomas Davis

as data, which immunogenicity will be had know, then, additional to we ASCO. able present Ben, since for the five us the who'll on presentation. patients And an patients data at you were in be three we've giving ESMO time available

data eight complete on you So, fairly look patients. can for

Benjamin Burnett

Okay.

vaccine B also the when also as Part we I expected you inhibitors? could guess, to get kind background efficacy to Apologize us is I how Great. guess, mid-next if still that. study of readout missed therapy, speak differentiate enables the wondering, do such I from data, the design of specifically, study? I versus the question about design well And checkpoint year. just the a of the was had I that Okay. year? expected next if

William Clark

depend between guidance Part year. that inhibitor effect. Yes. question the pace have Tom would vaccine, effect and we the next provide intend of I'll which exactly we to patients we updates with enroll the course, and and of checkpoint our with ongoing When we'll the Tom? how expect reiterate which data in the upon I as and, progress? vaccine of differentiate we we manufacture both the the speed will, Ben, specifically, B readout will answer middle

Thomas Davis

that so it question, from of in to innate what regimens. not can with of the constantly is comes challenges issue signal think obviously, the the that's far you separate field activity there's the inhibitor one up seeing the clear of But difficult as which a checkpoint So and I imagine. makes activity, we're the data

given what to be important what able it treatment a happened So, there people is data. if treatment there has a there's before add define most the you'll individual see should effect patients that clearly is the to them at vaccine what's what requires recognize prognostic then to comparison the a in you But what a months effect, and to assess you if in look But before clear happens their happens effect is group what and and it the they and as to cumulative overall after, tell it a to look really at each can instead responses, if better that have you phenomenon, at When see identify of determine statistics, and totality look changes. whether and individual factors, benefit. received is if course, you is. for vaccine changes of the them the thereafter, then, carefully

rates, be parallel. to rather at overall response focused due to and identifying and the ones not, on that shrinkage typically happens than individuals and clinical our were So, identify immunologic have looking which to specific in attempting focus inhibitor appear perhaps, checkpoint were which we'll which both

Operator

Needham from Chad next question Company. & from is the Messer And

Gil Blum

for on congrats is This Chad. progress. Gil, on the And

of on bit question a a here. follow-on, Just Ben's

point more get some we'll at some we at progression-related to So, data. immunogenicity going data? see ESMO Are

William Clark

clarify I assume? going to data if patients, asking just you're A we're progression from to Part have Gil, those

Gil Blum

that, in... that clearly, helped Not Yes. but

William Clark

Gil. have I I'll got answer Tom question. it. sure. that Thanks, No, Right.

Thomas Davis

on everybody to disease. having we'll the we therapy of Sure. their presentation. time remind adjuvant for in I be At at able give after the status these patients the presentation, update had are the the patients would that remission

who strong predict will to hard will outcomes. won't how as very very for not in it's will a be trend to patients and rapidly relapse that interested So, progress, certainly, But who those happen.

Gil Blum

of you the have on guys another And using results Any is, adjuvants other vaccine? systems been that question impressive for using. immunogenicity adjuvant Excellent. are pretty other or these your for delivery kind thoughts

William Clark

Gil. Thanks, I'll handle Yes. that.

GEN-XXX, program call the program not in for an most year, understand neoantigen our technologies. current vaccine think I of exploring as IND well the to in also disclosed alternate first half GEN-XXX, to As have adjuvant obviously intend We people we in cell file which our we therein. addition we have, yet as specifics have therapy, the delivery are development next the GEN-XXX we which and/or on in

this may to program opportunities any a I particular improvement have to on second behind arise is want from that the think that we thinking GEN-XXX for build the program.

the really of addition been long synthetic said, plus GEN-XXX the to the we're I the think, poly We think quite have possible the as using, has to vaccine as that. nature of a is compelling. ICLC. performance immune cancer we lead to from vaccine to generally want and that as deliver speaking, quickly benefit. as clinical to be and broad Thus and We quite pleased strong cheaply responses far, in what you've want peptides magnitude strong response the breadth; able with

we from take of the I the going want to the think it's GEN-XXX. to so, ongoing study readout clinical on which to our would determine investment And emphasize to clinical degree

So, waiting excited excited GEN-XXX, we're as is the GEN-XXX, we're very potentially about in about GEN-XXX and needed. very wings

Operator

is The next Baird. Mike Ulz from question from

Michael Ulz

starting B. on Part well as Congrats

a follow-up here. So maybe quick just B Part on

you protocol, flexible? is Just for it example, or checkpoint in of are guys more KEYTRUDA, restricting terms of use the inhibitor the say, the to

William Clark

Yes. Tom? question. the for Thanks, Mike,

Thomas Davis

Yes.

really that the path to course, of to is you for to you see and data gives identify what can to the can Our easiest vaccine which, best standard-of-care, the goal the forward compare add readout.

now time In tease have than come we the others into when to different designed Results current basically will types, the able that simply at tumor then with from those the the was be will able to vaccine PD-X-based the that differences PD-X need to combining benefits and with would continuum to to add will an to these, be building happens. identify through. out account appropriate the regimens five in we'll course. what So, these the we access should disease progressing others standard-of-care of some think we be standard-of-care patients, particular is what take regimens. the to what clinical able in similar the are of trial states trials are ways, to to. rather and to that between they have see somewhat what be on incorporate of leapfrog And data come benefits situation. We're But simply their done in standard-of-care patients appropriate course,

Michael Ulz

sense of if maybe cohorts; the just give And -- a you're patient you've us targeting you comment a you. Got in mentioned multiple numbers can there? can on you

William Clark

Mike. Thanks, Tom?

Thomas Davis

And The melanoma, and of refractory five head patients. proven the renal be to to will designed receive a checkpoint themselves include groups impacts is have to determine which Those there vaccination up in taking signals to patients XX in have inhibitors those similarly who initial Yes. each. are what order who cohorts, lung separate identify be will carcinomas. and cancer, group trial to designed urothelial can neck, patients

Operator

at question like to Chip to further time. Clark. no [Operator Mr. Instructions]. showing I this conference I back am turn the would

William Clark

Thank thanks, you, for Operator. everyone, And again, us today. joining

Operator

have Ladies today's participation, this day. and conference. concludes you Thank your a gentlemen, wonderful and for

all may disconnect. You

Genocea Biosciences (GNCAQ) 25 Jul 192019 Q2 Earnings call transcript